Company intelligence / Profile preview
BAR Pharmaceuticals s.r.l.
Reggio nell'Emilia, Reggio Emilia, Italybarrlabs.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
BAR Pharmaceuticals s.r.l. develops small molecule drugs targeting metabolic and liver diseases. Its lead candidate, BAR-502, an FXR/TGR5 agonist for nonalcoholic steatohepatitis (NASH), has entered Phase 1 clinical trials. Another candidate, BAR-704 for liver cirrhosis, is pending trial initiation. No published late-stage or commercial results as of early 2025[4].
- Therapeutic areas
- Gastroenterology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on BAR Pharmaceuticals s.r.l..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BAR Pharmaceuticals s.r.l..